ClinicalTrials.gg
Not yet recruitingNCT07811401Updated Oct 20, 2026

Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic Surgery

A Phase 2 interventional study of Lemborexant 5 mg and Placebo in Postoperative Sleep Disturbance and Thoracoscopic Surgery, sponsored by Beijing Tiantan Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Beijing Tiantan Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 20, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Video-assisted thoracoscopic surgery (VATS) is the mainstream minimally invasive procedure in thoracic surgery; However, the high-stress state during the perioperative period and severe postoperative pain often lead to significant disruption of patients' sleep patterns, thereby exacerbating postoperative pain sensitisation and delaying early recovery. Traditional sleep-inducing drugs, primarily benzodiazepines, have significant limitations in the perioperative period of thoracic surgery, including respiratory depression, dizziness and residual central effects, which hinder early ambulation. As a new-generation dual orexin receptor antagonist, Lemborexant exerts its sleep-promoting and anti-stress effects by precisely blocking excessive arousal pathways. Furthermore, it causes no respiratory depression, no hangover-like effects the following day, and does not impair muscle strength or mucus clearance, offering the potential to meet the dual requirements of sleep quality and high safety in Enhanced Recovery After Surgery (ERAS) protocols for thoracic surgery. However, there remains a lack of prospective clinical evidence regarding its application in the high-stress, high-pain perioperative acute cohort of thoracoscopic surgery. This study aims to conduct a prospective, randomised, double-blind, placebo-controlled clinical trial to improve perioperative sleep quality in VATS patients. The primary outcome measure of the study was the difference in the incidence of perioperative sleep disorders (PSD) between the two groups, as assessed by the total Richards-Campbell Sleep Questionnaire (RCSQ) score on the night of surgery. The study aims to investigate the causal relationship between short-term perioperative Lemborexant intervention and improvements in patient sleep and postoperative recovery quality. The anticipated results will provide clinical evidence of the safety and efficacy of Lemborexant for use in high-stress populations during the perioperative period.

02

Conditions studied

  • Postoperative Sleep Disturbance
  • Thoracoscopic Surgery
03

In context

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 493 studies on the registry; 297 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 70 years;
  • ;
  • Patients scheduled to undergo elective video-assisted thoracoscopic surgery (VATS) under general anaesthesia, including wedge resection, segmentectomy and lobectomy;
  • Pre-operative Pittsburgh Sleep Quality Index (PSQI) score > 5 points;
  • Expected post-operative hospital stay of ≥3 days;
  • Signing of a written form.

Exclusion criteria

Exclusion Criteria:

  • Patients whose surgery is expected to finish after 19:00, or who will remain intubated post-operatively or require admission to the ICU;
  • Patients with a pre-operative diagnosis of moderate to severe obstructive sleep apnoea (OSA);
  • Patients who take sedatives, sleeping tablets or antidepressants on a long-term basis;
  • Patients with moderate to severe hepatic or renal impairment;
  • Patients with cognitive impairment preventing them from cooperating with scale-based assessments;
  • Patients with pre-existing chronic neuropathic pain;
  • Patients unsuitable for or refusing to participate in this study for other. reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    lemborexant

    the intervention group

    Drug: Lemborexant 5 mg

  • Placebo comparator
    placebo

    the control group

    Drug: Placebo

Interventions

  • DrugLemborexantStudies of LemborexantLemborexant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention group will take Lemborexant tablets three times during the perioperative period

  • DrugPlacebo

    The control group will take placebo tablets with the same appearance, smell and properties as the intervention group three times during the perioperative period

06

What researchers measure

Primary outcomes

  1. The incidence of postoperative sleep disturbance (PSD)

    Differences in the incidence of perioperative sleep disorders (PSD) between the two groups, as assessed by the total score on the Richards-Campbell Sleep Questionnaire (RCSQ). The scale comprises five core items evaluating distinct sleep domains: sleep depth, sleep latency, frequency of awakenings, ability to return to sleep, and overall sleep quality. Each item is rated on a 100-mm visual analogue scale (VAS). The total score is calculated as the mean of the five core item scores, yielding a range from 0 to 100. A higher total score indicates better perceived sleep quality. Specifically, a score of 0 represents the worst possible sleep, while a score of 100 represents the best possible sleep.

    Time frame: The first night after the operation

Secondary outcomes

  1. Objective sleep quality

    Total sleep time (TST) and wake time after sleep onset (WASO) as monitored by the Huawei sleep tracker.

    Time frame: From the night before surgery to the second night after surgery (three consecutive nights).

  2. Postoperative pain scores

    Resting pain (NRS-R) and movement-induced pain (NRS-C) at 24 and 48 hours postoperation. Assessment was carried out using a numerical rating scale for pain intensity.

    Time frame: At 24 and 48 hours postoperation

  3. Postoperative anxiety and depression

    The Hospital Anxiety and Depression Scale (HADS) was used to assess changes in perioperative anxiety and depression subscale scores compared with baseline values.

    Time frame: The day before the operation and on the third day after the operation, or upon discharge

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 10, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 1, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • AddedPre-operative Pittsburgh Sleep Quality Index (PSQI) score > 5 points;
Exclusion criteria
  • EditedPatients with pre-existing sleep disorders or those takingwho take sedatives, hypnoticssleeping tablets or antidepressants on a long-term basis;
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Eligibility 1 inclusion criterion added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • AddedPre-operative Pittsburgh Sleep Quality Index (PSQI) score > 5 points;
    Exclusion criteria
    • EditedPatients with pre-existing sleep disorders or those takingwho take sedatives, hypnoticssleeping tablets or antidepressants on a long-term basis;
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07811401
Responsible party
Ruquan Han (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Sep 10, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemborexant

Start the discussion